Biocon Biologics Ltd (BBL), a unit of Biocon Ltd (BIOCON), Monday said that the U.S. Food and Drug Administration or FDA has approved Yesintek, a biosimilar to Johnson and Johnson's, Stelara.
Yesintek is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis.
Biocon had previously announced its settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson to commercialize Yesintek no later than on February 22, 2025, upon approval from the FDA.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.